News & Updates

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?

05 Sep 2023

Combination treatment with pembrolizumab and lenvatinib appears to be a better option for patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) with a platinum-free interval (PFI) of <6 months, suggests a recent study.

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?

05 Sep 2023

Blood test holds promise for early cancer detection

05 Sep 2023 by

In an interim analysis of the K-DETEK study, a noninvasive blood test was able to detect early-stage cancer and identify tumour location in asymptomatic individuals in Vietnam.

Blood test holds promise for early cancer detection

05 Sep 2023

Radiotherapy after ESD improves survival of patients with LVI in pT1b ESCC

04 Sep 2023

Adjuvant radiotherapy following endoscopic submucosal dissection (ESD) results in better survival in patients with lymphovascular invasion (LVI) in T1bN0M0 esophageal squamous cell cancer (ESCC), a study has shown.

Radiotherapy after ESD improves survival of patients with LVI in pT1b ESCC

04 Sep 2023

RT may be omitted after breast-conserving surgery in T1N0, grade 1/2, luminal A breast cancer

04 Sep 2023 by

Radiotherapy (RT) may be omitted in women ≥55 years of age with T1N0, grade 1 or 2, luminal A breast cancer who have been treated with breast-conserving surgery and endocrine therapy, due to the very low risk of 5-year local recurrence reported in a recent prospective cohort study.

RT may be omitted after breast-conserving surgery in T1N0, grade 1/2, luminal A breast cancer

04 Sep 2023

EUS-guided biliary drainage an option for unresectable malignant biliary obstruction

04 Sep 2023 by

Endoscopic ultrasound (EUS)–guided choledocho-doudenostomy (ECDS) can be an option for primary biliary drainage in patients with unresectable malignant distal biliary obstruction (MDBO), and may be preferred when endoscopic retrograde cholangiopancreatography (ERCP) is anticipated to be difficult, according an international randomized controlled trial (RCT) led by researchers from the Chinese University of Hong Kong (CUHK).

EUS-guided biliary drainage an option for unresectable malignant biliary obstruction

04 Sep 2023

The Geneva patient: Another score on the HIV remission board

01 Sep 2023 by

Another HIV patient may be on the way to a cure following stem cell therapy using wild-type (WT) CCR5 donor cells for a rare and aggressive blood cancer.

The Geneva patient: Another score on the HIV remission board

01 Sep 2023

Meta-analysis: TTFields added to SoC improves OS in newly diagnosed GBM in real-world setting

01 Sep 2023 by

Results of a systematic review and meta-analysis suggest that adding tumour-treating fields (TTFields) to standard chemoradiotherapy (CRT) significantly prolongs overall survival (OS) for patients with newly diagnosed glioblastoma multiforme (GBM) treated in the real-world setting.

Meta-analysis: TTFields added to SoC improves OS in newly diagnosed GBM in real-world setting

01 Sep 2023

Original New Drug Application Approvals by US FDA (16-31 August 2023)

01 Sep 2023

New drug applications approved by US FDA as of 16-31 August 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 August 2023)

01 Sep 2023

Do weak opioids increase risk of GI cancers?

30 Aug 2023 by

Evidence on the association of weak opioids with a higher risk of oesophageal and colorectal cancer is not reliable, but there appears to be a small association with gastric cancer, suggests a study.

Do weak opioids increase risk of GI cancers?

30 Aug 2023

Novel systemic therapies improve survival in prostate cancer patients with visceral metastasis

30 Aug 2023 by

Novel systemic treatments are similarly effective in reducing the risk of progression or death in patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC), irrespective of visceral metastasis status, reports a study.

Novel systemic therapies improve survival in prostate cancer patients with visceral metastasis

30 Aug 2023

News & Updates

Filter by Specialty:

Specialty:

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?

Blood test holds promise for early cancer detection

Blood test holds promise for early cancer detection

Radiotherapy after ESD improves survival of patients with LVI in pT1b ESCC

Radiotherapy after ESD improves survival of patients with LVI in pT1b ESCC

RT may be omitted after breast-conserving surgery in T1N0, grade 1/2, luminal A breast cancer

RT may be omitted after breast-conserving surgery in T1N0, grade 1/2, luminal A breast cancer

EUS-guided biliary drainage an option for unresectable malignant biliary obstruction

EUS-guided biliary drainage an option for unresectable malignant biliary obstruction

The Geneva patient: Another score on the HIV remission board

The Geneva patient: Another score on the HIV remission board

Meta-analysis: TTFields added to SoC improves OS in newly diagnosed GBM in real-world setting

Meta-analysis: TTFields added to SoC improves OS in newly diagnosed GBM in real-world setting

Original New Drug Application Approvals by US FDA (16-31 August 2023)

Original New Drug Application Approvals by US FDA (16-31 August 2023)

Do weak opioids increase risk of GI cancers?

Do weak opioids increase risk of GI cancers?

Novel systemic therapies improve survival in prostate cancer patients with visceral metastasis

Novel systemic therapies improve survival in prostate cancer patients with visceral metastasis